MA40589A - Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines - Google Patents

Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines

Info

Publication number
MA40589A
MA40589A MA040589A MA40589A MA40589A MA 40589 A MA40589 A MA 40589A MA 040589 A MA040589 A MA 040589A MA 40589 A MA40589 A MA 40589A MA 40589 A MA40589 A MA 40589A
Authority
MA
Morocco
Prior art keywords
progenitor cells
frizzled
jagged
ventricular progenitor
ventricular
Prior art date
Application number
MA040589A
Other languages
English (en)
Inventor
Kenneth R Chien
Xiaojun Lian
Original Assignee
Procella Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procella Therapeutics Ab filed Critical Procella Therapeutics Ab
Publication of MA40589A publication Critical patent/MA40589A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne jagged 1 et frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiomyogènes humaines, en particulier des cellules progénitrices qui se différencient préférentiellement en cellules musculaires ventriculaires cardiaques. Par conséquent, l'invention concerne des cellules progénitrices ventriculaires humaines (hvp), et des procédés de séparation in vitro de cellules progénitrices ventriculaires islet 1+/jagged 1+ et/ou de cellules progénitrices ventriculaires islet1+/frizzled 4+ et/ou de cellules progénitrices ventriculaires islet 1+/jagged 1+/frizzled 4+, et leur expansion et propagation à grande échelle. D'importantes populations clonales de cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ isolées sont également décrites. L'invention concerne également des procédés d'utilisation in vivo des cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ pour la réparation cardiaque ou pour l'amélioration de la fonction cardiaque. Des procédés d'utilisation des cellules progénitrices ventriculaires jagged 1+ et/ou frizzled 4+ pour le criblage de toxicité cardiaque de composés d'essai sont également décrits.
MA040589A 2014-08-22 2015-08-21 Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines MA40589A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462040892P 2014-08-22 2014-08-22
US201562194016P 2015-07-17 2015-07-17

Publications (1)

Publication Number Publication Date
MA40589A true MA40589A (fr) 2017-06-28

Family

ID=54062813

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040589A MA40589A (fr) 2014-08-22 2015-08-21 Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines

Country Status (6)

Country Link
US (1) US10597637B2 (fr)
EP (2) EP3183337B1 (fr)
JP (2) JP6738808B2 (fr)
DK (1) DK3183337T3 (fr)
MA (1) MA40589A (fr)
WO (1) WO2016029122A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40589A (fr) 2014-08-22 2017-06-28 Procella Therapeutics Ab Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
PT3417073T (pt) 2016-02-19 2023-10-26 Procella Therapeutics Ab Marcadores genéticos para enxerto de células progenitoras ventriculares cardíacas humanas
US20190136191A1 (en) * 2016-05-02 2019-05-09 Emory University Methods of Producing Specialized Cardio-Like Cells from Stem Cells
EP3519559A1 (fr) * 2016-09-30 2019-08-07 Wisconsin Alumini Research Foundation Progéniteurs cardiaques sensibilisés et procédés pour les préparer et les utiliser
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP7275109B2 (ja) * 2017-08-23 2023-05-17 プロセラ セラピューティクス アーベー ニューロピリン－１（ｎｒｐ１）のヒト心室前駆細胞を単離するための細胞表面マーカーとしての使用
CN109189051A (zh) * 2018-10-29 2019-01-11 江苏罗思韦尔电气有限公司 一种基于T-Box的故障存储及处理方法
US20220409855A1 (en) * 2021-06-29 2022-12-29 Staffan Holmin Methods of delivering cells and therapeutic agents to organs and extravascular sites
WO2023039588A1 (fr) * 2021-09-13 2023-03-16 FUJIFILM Cellular Dynamics, Inc. Procédés de production de cellules progénitrices cardiaques engagées
KR20250004778A (ko) 2022-04-15 2025-01-08 스마트셀라 솔루션즈 아베 mRNA 제제의 엑소좀-매개 전달을 위한 조성물 및 방법
GB202314218D0 (en) 2023-09-18 2023-11-01 Astrazeneca Ab Cell therapy
CN118897089B (zh) * 2024-08-09 2026-02-17 山西医科大学 Sarcolipin在早期无创诊断I型射血分数保留性心衰中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5561384A (en) 1995-11-08 1996-10-01 Advanced Micro Devices, Inc. Input/output driver circuit for isolating with minimal power consumption a peripheral component from a core section
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US5945577A (en) 1997-01-10 1999-08-31 University Of Massachusetts As Represented By Its Amherst Campus Cloning using donor nuclei from proliferating somatic cells
US7166280B2 (en) 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
CA2465672A1 (fr) 2001-09-19 2003-03-27 Henry Ford Health System Transplantation cardiaque de cellules souches pour le traitement de l'insuffisance cardiaque
CA2514810A1 (fr) * 2003-01-31 2004-08-19 The Regents Of The University Of California Utilisation de l'ilot 1 comme marqueur pour isoler ou produire des cellules souches
US20080038229A1 (en) 2006-08-08 2008-02-14 Minguell Jose J Intracoronary injection of a mixture of autologous bone marrow derived mononuclear cells and autologous bone marrow derived mesenchymal stem cells for utilization and rescue of infarcted myocardium
US20100166714A1 (en) 2006-11-02 2010-07-01 The General Hospital Corporation Cardiovascular stem cells, methods for stem cell isolation, and uses thereof
KR101240487B1 (ko) 2006-11-09 2013-03-08 더 존스 홉킨스 유니버시티 성체 포유동물 심근세포의 심장 줄기 세포로의 역분화
US20080182328A1 (en) 2006-12-19 2008-07-31 The Burnham Institute Mammalian extraembryonic endoderm cells and methods of isolation
EP2222837A2 (fr) 2007-02-09 2010-09-01 The General Hospital Corporation Procédés d'induction de l'entrée d'une cellule dans la lignée des cellules isl1+ et procédé d'expansion de ladite lignée
AU2007357127B2 (en) 2007-07-31 2014-06-26 Es Cell International Pte Ltd Method for identifying and selecting cardiomyocytes
EP2245140A2 (fr) * 2007-11-30 2010-11-03 New York Medical College Compositions comprenant des inhibiteurs hdac et procédés permettant de les utiliser pour réparer la fonction des cellules souches et empêcher l'insuffisance cardiaque
US20120027807A1 (en) 2008-10-09 2012-02-02 The General Hospital Corporation Tissue engineered myocardium and methods of production and uses thereof
WO2011091945A1 (fr) * 2010-01-26 2011-08-04 Université Libre de Bruxelles Outils pour isoler et suivre des cellules progénitrices cardiovasculaires
WO2011153236A1 (fr) * 2010-06-03 2011-12-08 The Board Of Trustees Of The Leland Stanford Junior University Compositions purifiées contenant des cellules progénitrices cardio-vasculaires
US20120009158A1 (en) * 2010-06-18 2012-01-12 The General Hospital Corporation VENTRICULAR INDUCED PLURIPOTENT STEM (ViPS) CELLS FOR GENERATION OF AUTOLOGOUS VENTRICULAR CARDIOMYOCYTES AND USES THEREOF
WO2012070014A2 (fr) 2010-11-26 2012-05-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Identification de nouveaux marqueurs de surface cellulaire pour des cellules progénitrices pancréatiques et des cellules endodermiques définies
WO2012162741A1 (fr) * 2011-06-01 2012-12-06 Monash University Enrichissement de cardiomyocytes
WO2013056072A1 (fr) 2011-10-13 2013-04-18 Wisconsin Alumni Research Foundation Génération de cardiomyocytes à partir de cellules souches pluripotentes humaines
JP5920741B2 (ja) 2012-03-15 2016-05-18 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 人工多能性幹細胞から心筋および血管系混合細胞群を製造する方法
WO2014078414A1 (fr) 2012-11-13 2014-05-22 Joseph Wu Production définie chimiquement de cardiomyocytes à partir de cellules souches pluripotentes
WO2014150602A1 (fr) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Essai d'activité biologique de cellules pour un potentiel thérapeutique
WO2015058117A1 (fr) 2013-10-18 2015-04-23 Icahn School Of Medicine At Mount Sinai Spécification ventriculaire des cellules souches et différenciation dirigée en cardiomyocytes
EP2875819B1 (fr) 2013-11-20 2018-09-19 Miltenyi Biotec GmbH Compositions de sous-populations de cardiomyocytes
WO2015123325A1 (fr) * 2014-02-12 2015-08-20 Genentech, Inc. Anticorps anti-jagged1 et procédés d'utilisation correspondants
WO2015166638A1 (fr) * 2014-05-01 2015-11-05 ｉＨｅａｒｔ Ｊａｐａｎ株式会社 Cellules progénitrices cardiaques positives pour le cd82
MA40589A (fr) 2014-08-22 2017-06-28 Procella Therapeutics Ab Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
US10596200B2 (en) 2014-08-22 2020-03-24 Procella Therapeutics Ab Use of LIFR or FGFR3 as a cell surface marker for isolating human cardiac ventricular progenitor cells
EP3259348A4 (fr) 2015-02-17 2018-07-18 University Health Network Procédés de production et d'utilisation de cardiomyocytes stimulateurs de type noeud sino-auriculaire et de cardiomyocytes de type ventriculaire
PT3417073T (pt) 2016-02-19 2023-10-26 Procella Therapeutics Ab Marcadores genéticos para enxerto de células progenitoras ventriculares cardíacas humanas
US10508263B2 (en) 2016-11-29 2019-12-17 Procella Therapeutics Ab Methods for isolating human cardiac ventricular progenitor cells

Also Published As

Publication number Publication date
WO2016029122A1 (fr) 2016-02-25
EP3183337B1 (fr) 2019-02-06
US10597637B2 (en) 2020-03-24
EP3524673A1 (fr) 2019-08-14
DK3183337T3 (en) 2019-04-01
US20160053229A1 (en) 2016-02-25
JP2020120677A (ja) 2020-08-13
EP3183337A1 (fr) 2017-06-28
JP6738808B2 (ja) 2020-08-12
JP2017525393A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
MA40589A (fr) Utilisation de jagged 1/frizzled 4 à titre de marqueurs de surface cellulaire pour isoler des cellules progénitrices ventriculaires cardiaques humaines
EA201290527A1 (ru) Способы выделения мононуклеарных клеток, которые включают субпопуляцию мезенхимальных клеток-предшественников, и сосудистых клеток, которые включают субпопуляцию эндотелиальных клеток-предшественников, из пуповинной ткани
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EP4606890A3 (fr) Échafaudages mimétiques de cellules présentant un antigène et leurs procédés de fabrication et d'utilisation
MX2025010535A (es) Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia
EA202091219A1 (ru) Культивирование плаценты с целью выделения экзосом
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
EA201491473A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
MY192522A (en) Defined composition gene modified t-cell products
MX2016011686A (es) Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2015154012A8 (fr) Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations
EP3769775A3 (fr) Compositions pour lier des domaines de liaison à l'adn et des domaines de clivage
EA201790357A1 (ru) Способ получения клеток-предшественников зрелой печени
MX2014014027A (es) Modulacion por hutc de mediadores proinflamatorios de pulmon y enfermedades y trastornos pulmonares.
MX2019007890A (es) Compuestos de 1h-pirrol-2,5-diona y metodos de uso de los mismos para inducir la auto-renovacion de celulas madre/progenitoras de soporte.
WO2015181831A3 (fr) Procédé pour cibler un glioblastome avec des cellules souches mésenchymateuses de la gelée de wharton (cms-gw) dérivées de cordon ombilical humain
EP4497477A3 (fr) Synthèse améliorée de l'inhibiteur d'antigène membranaire spécifique de la prostate (psma) radiomarqué [18f!dcfpyl
MX2021012041A (es) Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas.
MX2016016756A (es) Terapia con células madre en patologías endometriales.
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
HK1251623A1 (zh) T细胞耗尽或缺乏t细胞共刺激的检测及其用途
WO2018140850A3 (fr) Lymphocytes t dérivés de sang de cordon ombilical
ZA201908062B (en) Selection and use of umbilical cord cell fractions suitable for transplantation